#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13374	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2176	606.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1582	1582	C	746	C	721	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13374	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2176	606.2	0	HET	.	.	.	C519T	.	519	519	C	917	917	C	816	C,T	598,202	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24836	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3735	657.8	0	.	n	.	0	T695C	SNP	695	695	T	1150	1150	C	708	C,A	692,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24836	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3735	657.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1792	1792	A	827	A	816	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24836	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3735	657.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2426	2426	C	753	C	737	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24836	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3735	657.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3052	3052	T	749	T	735	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24836	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3735	657.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2500	2500	A	770	A	754	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24836	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3735	657.8	0	HET	.	.	.	G540A	.	540	540	G	995	995	G	803	G,A	587,187	.	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	16	blaTEM	861	298	100.0	blaTEM.l15.c30.ctg.1	351	3.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1728	folP	852	852	100.0	folP.l15.c4.ctg.1	1603	106.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1016	1018	AGC	167;168;169	A;G;C,A	163;164;161,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4870	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3458	139.2	1	SNP	p	S91F	0	.	.	271	273	TCC	580	582	TCC	153;148;149	T;C,A;C	149;145,1;148	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4870	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3458	139.2	1	SNP	p	D95G	0	.	.	283	285	GAC	592	594	GAC	148;146;148	G;A;C	145;142;146	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4870	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3458	139.2	1	SNP	p	D95N	0	.	.	283	285	GAC	592	594	GAC	148;146;148	G;A;C	145;142;146	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1450	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1369	105.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	465	467	ACC	153;153;151	A;C;C	142;147;145	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1450	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1369	105.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	480	482	CAC	150;151;150	C;A;C	148;146;148	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1450	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1369	105.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	663	665	CAC	186;186;186	C;A,C;C	181;174,1;179	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1450	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1369	105.3	1	SNP	p	G45D	0	.	.	133	135	GGC	483	485	GGC	150;151;147	G;G;C	146;148;145	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	822	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	837	96.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4360	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2875	149.9	1	SNP	p	D86N	0	.	.	256	258	GAC	526	528	GAC	174;174;174	G,A;A;C	166,1;165;169	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4360	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2875	149.9	1	SNP	p	S87R	0	.	.	259	261	AGT	529	531	AGT	173;178;174	A,G;G;T	169,1;171;165	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4360	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2875	149.9	1	SNP	p	S87W	0	.	.	259	261	AGT	529	531	AGT	173;178;174	A,G;G;T	169,1;171;165	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4360	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2875	149.9	1	SNP	p	S87I	0	.	.	259	261	AGT	529	531	AGT	173;178;174	A,G;G;T	169,1;171;165	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4360	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2875	149.9	1	SNP	p	S88P	0	.	.	262	264	TCC	532	534	TCC	172;173;175	T;C,G;C,A	167;166,1;170,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3620	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2507	142.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1447	1449	GGC	199;191;186	G;G,A;C	191;183,1;177	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1180	1182	GCA	176;176;177	G,A;C;A	170,1;168;174	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1183	1185	ATC	176;176;178	A;T;C	173;173;173	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1195	1197	GTG	180;179;176	G;T;G	176;174;173	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1195	1197	GTG	180;179;176	G;T;G	176;174;173	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1699	1701	ACC	168;167;167	A;C;C	158;164;164	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1753	1755	GCG	154;150;151	G;C,G;G,C,A	145;128,1;137,1,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1753	1755	GCG	154;150;151	G;C,G;G,C,A	145;128,1;137,1,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1876	1878	GGC	131;130;127	G;G;C	123;121;118	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1885	1887	GGC	119;118;116	G;G;C	113;111;114	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3362	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2244	147.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1903	1905	CCG	105;106;106	C,G;C;G,C	98,2;97;89,2	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5004	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3179	155.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1650	1652	CTG	198;197;196	C;T,C;G	191;185,1;189	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2030	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1812	110.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	557	557	C	156	C	148	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	438	440	GGA	206;206;209	G;G;A	198;197;199	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	699	701	CTT	175;175;175	C;T;T	170;173;172	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	723	725	GGA	175;175;176	G;G;A	173;172;169	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	0	.	p	.	0	D171G	NONSYN	511	513	GAT	807	809	GGT	163;163;163	G;G;T	160;162;156	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	861	863	AGC	191;193;193	A;G;C	185;188;187	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	927	927	T	177	T	169	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	1	SNP	p	G120K	0	.	.	358	360	GGT	654	656	GGT	180;183;185	G;G;T,G	172;174;170,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	1	SNP	p	A121D	0	.	.	361	363	GCC	657	659	GCC	184;185;189	G;C;C	174;177;179	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2408	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1564	152.1	1	SNP	p	A121N	0	.	.	361	363	GCC	657	659	GCC	184;185;189	G;C;C	174;177;179	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8832	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4799	181.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1932	1934	AAT	201;200;199	A;A;T	195;192;190	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1110	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1097	100.4	1	SNP	p	V57M	1	.	.	169	171	ATG	542	544	ATG	229;229;226	A;T;G	222;220;221	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
